

61st Annual Scientific Meeting of the American Headache Society

POSTER PRESENTATIONS

Friday, July 12 and Saturday, July 13, 2019

- P01** Central Mechanisms of Cortical Spreading Depression Inhibition by Vagus Nerve Stimulation
Morais, Andreia
- P02** Cortical Spreading Depression Inhibition by Non-invasive Vagus Nerve Stimulation: Dose-response and Duration of Effect
Morais, Andreia
- P03** Early Life Stress-induced Increases in Cortical Spreading Depression Susceptibility and Anxiety Are Not Expressed in the Progeny of Stressed Male Rats
Collins, Stuart
- P04** Maternal Separation-induced Increases in CrhR1 Expression Within the Occipital Cortex and Hippocampus
Collins, Stuart
- P05** Early Life Stress Promotes Development of a Sensitized Trigeminal System and Gut Dysbiosis That Is More Severe in Females
Durham, Paul
- P06** Noninvasive Vagus Nerve Stimulation and Morphine Transiently Inhibit Trigeminal Pain Signaling in a Chronic Migraine Model
Durham, Paul
- P07** The Role of Cerebellar CGRP in Migraine-like Behavior
Wang, Mengya
- P08** Effect of Yoga as Add on Therapy in Migraine (CONTAIN): A Randomized Controlled Study
Kumar, Anand
- P09** CGRP Antibodies as Adjunctive Prophylactic Therapy for Prolonging the Therapeutic Effect of OnabotulinumtoxinA Injections Among Chronic Migraine Patients
Yuan, Heidi
- P10** A Real-world Assessment of the Impact on the Health-related Quality of Life and Work Productivity of Triptan Non-responders Compared with Responders: Results from a Global Study
Lombard, Louise
- P11** Early Detection of Persons at Risk for Incident CM
Iaconangelo, Charles
- P12** Eptinezumab Reduces the Frequency of Headaches and Migraines in Patients with Episodic or Chronic Migraine: Results from the PROMISE 1 and PROMISE 2 Trials
Mechtler, Laszlo

- P13** OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study
Rothrock, John
- P14** The Impact of OnabotulinumtoxinA vs Placebo on Efficacy Outcomes in Responder and Nonresponder Subgroups of Patients with Chronic Migraine: PREEMPT Pooled Analysis
Diener, Hans-Christoph
- P15** Multiple Sclerosis and Headache: A Further Examination of These Comorbid Conditions in Patients Receiving Care in a Multiple Sclerosis Center: A Cross-Sectional Study
Minen, Mia
- P16** Reduced Impact of Headaches After Migraine Preventive Treatment with Eptinezumab in Patients with Chronic Migraine: Results from the PREVAIL Open-Label Safety Study
Spierings, Egilius
- P17** Eptinezumab Treatment for Migraine Prevention Reduces Migraine Disability in Patients with Chronic Migraine: An Analysis from the PREVAIL Open-Label Safety Study
Kudrow, David
- P18** The Effect of Lacosamide on Chronic Migraine: Retrospective Analysis in a Single Center Academic Headache Center
Yuan, Heidi
- P19** Early Prescribing Patterns of the Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies Are Dominated by Adjunctive Use for Episodic and Chronic Migraine Prevention: Trending the First Year of US Adoption
Schobel, Virginia
- P20** The Aimovig "Wear-Off": A Retrospective Review
Feldman, Daniel
- P21** Patient Engagement and Patient Centered Research: The Results of Four Focus Groups on the Migraine Patient Experience During Research Studies and Their Ideas for Study Design Consideration in Future Studies
Minen, Mia
- P22** Impact of US Physicians' Perceptions of the Distinct Pharmacological and Clinical Characteristics of the Novel Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Self-Reported Chronic Migraine Prevention Brand Share
Schobel, Virginia
- P23** Effectiveness of Erenumab on High Frequency Migraine Patients in a Tertiary Center
Preston, Juliette
- P24** Detecting Factors Associated with "low" and "high" Headache Pain Days in Individuals with Chronic Migraine
Donoghue, Stephen
- P25** Longitudinal Preventive Medication Use Patterns in Patients Receiving OnabotulinumtoxinA Treatment: A Chart Review Study
Burch, Rebecca

- P26** Tolerability of Three Additional Neck Injection Sites During OnabotulinumtoxinA Therapy Following the PREEMPT Injection Paradigm for Chronic Migraine
Khan, Fawad
- P27** Up in Smoke: Erenumab Induced Nausea Exacerbated by Smoking Resulting in Smoking Cessation
Mathew, Paul
- P28** A Survey of American Headache Society Members on Treatment of Migraine in Pregnancy
Hamilton, Katherine
- P29** Elective Hospitalizations for Intractable Headache: Outcomes and Response Predictors
Kiarashi, Jessica
- P30** DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Efficacy Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Lipton, Richard
- P31** Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by the POD[®] Device Compared to D.H.E. 45[®] for Injection from the STOP 101 Clinical Trial
Craig, Karen
- P32** The Medication Overuse Treatment Strategy (MOTS) Trial: Description of the Patient Cohort at Baseline
Schwedt, Todd
- P33** Galcanezumab Safety/tolerability Profile Does Not Differ in Patients with Episodic or Chronic Migraine
Stauffer, Virginia
- P34** Real-World Experience with CGRP-antagonists in the Treatment of Migraine
Bucklan, Julie
- P35** Long-Term Safety of Fremanezumab: Results of a 1-Year Study
Ning, Xiaoping
- P36** Control of the Placebo Response in Migraine Induction Models
CONNELL, JOHN
- P37** Safety, Tolerability and Comparative Pharmacokinetics of a Novel, Dry Powder Intranasal DHE Product (STS101)
Albrecht, Detlef
- P38** Post-Market Observational Study of Patient Experience with Erenumab
Robblee, Jennifer
- P39** Changes in MIDAS, Perceived Stress, Frontalis Muscle Activity and NSAID Usage in Patients with Migraine Headache Without Aura Following Ayurveda and Yoga Compared to Controls: An Open Labeled Non-randomized Study
Sharma, Vasudha
- P40** Treatment of Trigeminal Neuralgia Using the TX360 Device
Freitag, Frederick
- P41** Rimegepant 75 Mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine

Croop, Robert

- P42** Riboflavin and Micronutrient Deficiencies in Patients with Migraine--A Case Series with Documented Blood Levels and Response to Treatment of Nutritional Deficiencies
Achari, Madhureeta
- P43** The Effectiveness of Essential Oils on Headaches
Sheikh, Huma
- P44** STOP 301: Open-label Safety and Tolerability of Chronic Intermittent Usage for 24/52 Weeks of INP104 [Nasal Dihydroergotamine Mesylate (DHE) Administered by Precision Olfactory Delivery (POD®) Device] in Migraine Headache
Shrewsbury, Stephen
- P45** The Impact of Shift Work on Migraine: A Case Series and Literature Review
Sandoe, Claire
- P46** Safety and Tolerability of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Safety Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Munjal, Sagar
- P47** Cluster Headache Is One of the Most Painful Human Conditions: Epidemiology of Cluster Headache and Probable Cluster Headache from a Large International Sample
Burish, Mark
- P48** Vascular Risk Associations in Cluster Headache: A Case Control Study from India
Chowdhury, Debashish
- P49** The Headache That Broke My Heart
Singh, Jyotika
- P50** Symptomatic SUNA heralding a lateral medullary infarction: A case of a sentinel trigeminal autonomic cephalgia
Robblee, Jennifer
- P51** Prevalence of Gastric Ulcer Disease (UD) and Association with NSAID Use Among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment (MAST) Study
Lipton, Richard
- P52** Understanding Practice Patterns Surrounding the Use of Hormonal Therapies in Migraine: results from the Women's Health Migraine Survey
Grosberg, Brian
- P53** Who Is Eligible for Novel Medications Designed for the Acute Treatment of Migraine and What Are Their Unmet Needs? Results of the OVERCOME Study
Lipton, Richard
- P54** Impact of Migraine Headache Day Frequency on Associated Health : Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
Lipton, Richard

- P55** Identifying Sociodemographics and Symptoms Associated with Emergency Department and Urgent Care Use in People with Migraine: Survey Results from Migraine in America Symptoms and Treatment Study
Schwedt, Todd
- P56** Symptom Patterns, Disability, and Physician Visits Among a US Sample of People with Migraine: Results of the OVERCOME Study
Reed, Michael
- P57** A Real-World Analysis of the Burden of Migraine in Patients with Prior Treatment Failure: Evidence from the BECOME Study
Lucas, Christian
- P58** Meaningful Relief Measurement: Analysis of Responses to a Survey of Patient Priorities
Smith, Timothy
- P59** Headache Evaluation and Treatment: results from the Women's Health Migraine Survey
Grosberg, Brian
- P60** Evaluating the Relationship of Healthcare Professional-Patient Communication, Treatment and Satisfaction: Results from Migraine in America Symptoms and Treatment Study
Buse, Dawn
- P61** Rates of Associated Health Conditions in Those with Migraine vs. Non-migraine Controls: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
Alam, Aftab
- P62** Characteristics of Migraine Patients Visiting the European Headache Specialist Centers: Real-World Evidence from the Multinational BECOME Study
Pozo-Rosich, Patricia
- P63** Migraine Prevalence, Disease and Comorbidity Burden, and Evidence-based Practice Guideline Knowledge: results from the Women's Health Migraine Survey
Minen, Mia
- P64** Factors Associated with Most Bothersome Non-Headache Migraine Symptom (Nausea, Photophobia and Phonophobia): Results from the Migraine in America Symptoms and Treatment (MAST) Study
Munjal, Sagar
- P65** Assessment of Prevalence and Knowledge Knowledge of Migraine Headache in Northeast Nigeria
Ali, Mohammed
- P66** Network Analysis of the International Classification of Headache Disorders, 3rd Edition
Zhang, Pengfei
- P67** A Surveillance of the Tortuous Path from Primary Care to Headache Specialist
Lin, Jason
- P68** Prevalence and Incremental Healthcare Costs of Comorbid Depression in Migraine Care
Kee, Arianna
- P69** Digital Therapeutics Treatment of Migraine
Schenker, Eran

- P70** Epidemiology of Headache in Latin America: A Systematic Review and Meta-analysis of Its Prevalence and Incidence
Pacheco-Barrios, Kevin
- P71** 10-Year Cost-Effectiveness Analyses of Fremanezumab as Preventive Treatment in Chronic and Episodic Migraine
Smolen, Lee
- P72** A RETROSPECTIVE COMMUNITY BASED STUDY EVALUATING DISABILITY in MIGRAINE PATIENTS TREATED with ERENUMAB-aooe
Turner, Ira
- P73** Economic Aspects of Establishing Prior Use of Two Oral Triptans Before Starting Novel Acute Treatments for Migraine
Pohl, Gerhardt
- P74** Impact of Migraine on the Prevalence and Clinical Presentation of Depression: A Population-based Study
Chu, Min Kyung
- P75** Development of a Patient Reported Outcome Measure Evaluating Meaningful Response to Migraine Treatment
Cady, Ryan
- P76** Systematic Review of Clinical Studies Evaluating Non-invasive Neuromodulation for Migraine and Cluster Headache
Reuter, Uwe
- P77** Scoping Review of Migraine and Air Pollution Studies
Portt, Andrea
- P78** Association of Migraine and Asthma in Pediatric Patients: A National Perspective on Gender and Racial Disparities
Patel, Riddhiben
- P79** Benign Paroxysmal Torticollis: Phenotype, Natural History and Future Research Directions
Greene, Kaitlin
- P80** Paracetamol versus Ibuprofen for the Acute Treatment of Migraine Headache in Children
VASUDEVAN, PAVITHRA
- P81** Pediatric Screen Exposure and Headache Disability
Langdon, Raquel
- P82** Efficacy of Sphenopalatine Ganglion Blocks in a Pediatric Headache Practice
Holick, Michelle
- P83** Prognosis of New Daily Persistent Headache in Children and Adolescents
Simmons, Adrienne
- P84** Title: Headache Prevalence in Transgender Youth: A Retrospective Chart Review
Hranilovich, Jennifer
- P85** Headache Frequency in Children After Hemispherectomy

Pandit, Ishani

- P86** A Curious Case of Headache
Pai B.H, Poonam
- P87** Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
Dodick, David
- P88** Safety and Tolerability of Ubrogepant Following Intermittent, High-Frequency Dosing
Goadsby, Peter
- P89** Opioid Use, Rebound Headache, and Resource Utilization Among Migraine Patients with Insufficient Response to Triptans Based on Real-World Data
Shewale, Anand
- P90** Triptan Discontinuation and Treatment Patterns Among Migraine Patients Initiating Triptan Treatment in a United States Commercially Insured Population
Marcus, Steven
- P91** Analysis of Treatment Change of Acute Prescription Migraine Medications Using Real-World Evidence
Lipton, Richard
- P92** Greater Headache-Related Burden and Disability Among Those with Medication Overuse: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Schwedt, Todd
- P93** Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults
Jakate, Abhijeet
- P94** Health-Related Quality of Life Based on Response to Triptans in People with Migraine: Analysis of Real-World Data
Lipton, Richard
- P95** Coadministration of Single Therapeutic Oral Doses of Ubrogepant and Sumatriptan Produces No Clinically Relevant Pharmacokinetic Interactions
Jakate, Abhijeet
- P96** Single Therapeutic Doses of Ubrogepant Are Not Associated with a Clinically Relevant Drug-Drug Interaction When Co-administered with Acetaminophen or Naproxen
Jakate, Abhijeet
- P97** Absence of Clinically Significant Drug Interactions with Co-administration of Atogepant and an Ethinyl Estradiol–Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
Ankrom, Wendy
- P98** Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor
Moore, Eric
- P99** Educating Patients on New Treatments:

The Experience of One Headache Center's Launch of the New CGRP Migraine Medications
Wells, Rebecca

- P100** Absence of Clinically Significant Drug Interactions with Coadministration of Ubrogepant and an Ethinyl Estradiol/Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
Li, Chi-Chung
- P101** Pressing Issues Among New Investigators and Trainees in Headache: Results of a Survey of the American Headache Society New Investigator and Trainee Section and International Headache Academy Attendees
VanderPluym, Juliana
- P102** A Proposed Structure for the Study of the History of Headache Medicine
Rosen, Noah
- P103** Ubrogepant Achieves Onset of Pain Relief at 1 Hour for the Acute Treatment of Migraine
Dodick, David
- P104** Onset of Efficacy Following Oral Treatment with Lasmiditan for the Acute Treatment of Migraine
Vasudeva, Raghavendra
- P105** Efficacy and Safety of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the Multicenter, Randomized, Placebo-controlled FOCUS Study
Ferrari, Michel
- P106** Effect of a Rescue or Recurrence Dose of Lasmiditan on Efficacy and Safety in the Acute Treatment of Migraine: Findings from the Phase 3 Trials (SAMURAI and SPARTAN)
Loo, Li Shen
- P107** Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Silberstein, Stephen
- P108** Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine
Rizzoli, Paul
- P109** Long-term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine Attacks
Ailani, Jessica
- P110** Long-term Response Rates in Chronic and Episodic Migraine Patients with Concomitant Preventive Medication Use: Results from 1-Year Study
Goadsby, Peter
- P111** Temporal Response Patterns to Erenumab in Patients with Chronic Migraine
Tepper, Stewart
- P112** An Optional Second Dose of Ubrogepant Is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine
Ailani, Jessica

- P113** Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study
Goadsby, Peter
- P114** Effects of Lasmiditan on Cardiovascular Parameters in Healthy Subjects Receiving Oral Doses of Propranolol
Wilbraham, Darren
- P115** Patient Functioning and Disability Among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
McAllister, Peter
- P116** Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab Among Patients with Episodic and Chronic Migraine
Wietecha, Linda
- P117** Efficacy of Erenumab in Chronic Migraine Patients with and Without Allodynia
Lipton, Richard
- P118** Long-Term Efficacy of Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
Lipton, Richard
- P119** Improvement in Migraine Pain Severity in Patients Treated with Erenumab
Lipton, Richard
- P120** How Adverse Events Are Collected and Reported: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
Krege, John
- P121** Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy
Buchanan, Andrew
- P122** Shift from Chronic Migraine to Episodic Migraine Status in a Long-Term Phase 3 Study of Galcanezumab
Hindiyeh, Nada
- P123** Long-Term Impact of Fremanezumab on Response Rates: Results of a 1-Year Study
Newman, Lawrence
- P124** Safety of Ubrogepant in Participants with Moderate to High Cardiovascular Risk
Hutchinson, Susan
- P125** PREVAIL: An Open-Label Phase 3 TRIal to EValuate the Safety of Eptinezumab Administered Intravenously in Patients with Chronic Migraine
Allan, Brent
- P126** Temporal Response Patterns to Erenumab in Patients with Episodic Migraine
McAllister, Peter
- P127** Real-world Use of Non-invasive Vagus Nerve Stimulation for Acute Treatment of Pain in Episodic Cluster Headache: Results from a Patient Registry
Liebler, Eric

- P128** The Impact of Fremanezumab on the Maximum Number of Consecutive Days Without Headaches of at Least Moderate Severity in Patients with Chronic Migraine
Silberstein, Stephen
- P129** Long-term Efficacy of Fremanezumab in Migraine Patients with and Without Concomitant Oral Preventive Medication Use: Results of a 1-Year Study
Goadsby, Peter
- P130** Long-Term Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Migraine Patients with Concomitant Preventive Medication Use: Results of a 1-Year Study
Lipton, Richard
- P131** Improvement in Response over Time with Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
Halker Singh, Rashmi
- P132** Healthcare Resource Utilization in Adult Patients Treated with OnabotulinumtoxinA for Chronic Migraine: Results from the COMPEL Study
Rothrock, John
- P133** Efficacy and Safety of Lasmiditan in Patients on Concomitant Migraine Preventive Medications: Findings from SAMURAI and SPARTAN Phase 3 Trials
Schim, Jack
- P134** Comparison of Early Plasma Exposure of DHE Following Nasal, Oral Inhalation, or Intravenous Administration
Satterly, Kelsey
- P135** Efficacy Is Maintained with Long-term Intermittent Use of Ubrogepant for the Acute Treatment of Migraine
Lipton, Richard
- P136** Improvement in Headache-related Disability with Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the International, Multicenter, Randomized FOCUS Study
Ashina, Messoud
- P137** Sustained Response to Erenumab over Time in Patients with Episodic Migraine
McAllister, Peter
- P138** Eptinezumab Improved Health-Related Quality of Life in Patients with Chronic Migraine in the Open-Label PREVAIL Study
Kassel, Eric
- P139** The Impact of Fremanezumab on the Maximum Number of Consecutive Days Without Migraine in Patients with Episodic Migraine
Dodick, David
- P140** Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Chronic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Silberstein, Stephen

- P141** Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Lipton, Richard
- P142** Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine: Results of a 1-Year Study
McAllister, Peter
- P143** Long-Term Impact of Fremanezumab on Headache-Related Disability, Quality of Life, and Patient Satisfaction in Episodic Migraine and Chronic Migraine
Cohen, Joshua
- P144** Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine and Comorbid Moderate to Severe Depression
Lipton, Richard
- P145** Effects of Lasmiditan When Coadministered with Sumatriptan: Results of a Randomized, Double-Blind, Crossover Study in Healthy Subjects
Berg, Paul
- P146** Effects of Lasmiditan When Coadministered with Topiramate: Results of a Parallel, Placebo-Controlled, Fixed-Sequence Study in Healthy Subjects
Berg, Paul
- P147** Long-Term Impact of Fremanezumab on Headache-Related Disability and Quality of Life in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
Ailani, Jessica
- P148** Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications
Ferrari, Michel
- P149** Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine with Concomitant Preventive Medication Use
Goadsby, Peter
- P150** Sustained Response to Erenumab over Time in Patients with Chronic Migraine
Tepper, Stewart
- P151** Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
Winner, Paul
- P152** Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine Who Have Failed at Least One Prior Preventive Migraine Medication: Results of a 1-Year Study
McAllister, Peter
- P153** Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed at Least One Prior Preventive Migraine Medication: Results of a 1-Year Study
Brandes, Jan

- P154** Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability from ACHIEVE I and ACHIEVE II Phase 3 Studies
Hutchinson, Susan
- P155** Quarterly Administration of Fremanezumab Does Not Show “Wearing Off” Effect During Third Month After Injection
Blaiss, Cory
- P156** The Effect of Migraine Headache Intensity on the Efficacy of Low-Dose (3 Mg) Sumatriptan Injection (DFN-11) in the Acute Treatment of Episodic Migraine Attacks: From the RESTOR Study
Munjaj, Sagar
- P157** Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
Brandes, Jan
- P158** An Open-Label Phase 3 Trial to Evaluate the Safety of Eptinezumab Administered Intravenously in Patients with Chronic Migraine (PREVAIL): Demographics and Baseline Characteristics
Song, Yanyu
- P159** Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Results of a 1-Year Study
Brandes, Jan
- P160** Depression and Anxiety Are Associated with Increased Headache-Related Disability in Episodic and Chronic Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Lipton, Richard
- P161** Features of Episodic Cluster Headache in the Real World Setting: Clinical Characteristics from a Large, Multi-national, Cross-sectional Survey
Martinez, James
- P162** Characteristics of Headaches and Premonitory Symptoms During the Run-in Phase of a Large Migraine Trial
Schmidt, Peter
- P163** Healthcare Resource Use and Humanistic Burden Associated with Attack Frequency in Episodic Cluster Headache
Andrews, J. Scott
- P164** Characteristics of Patients Receiving Preventive Treatment Among Prevention-eligible Patients with Migraine
Mason, Oksana
- P165** Characteristics of Early Users of Erenumab in a Large US Administrative Claims Database
Chia, Victoria
- P166** Dihydroergotamine, Then and Now
Ray, Sutapa
- P167** The Association Between Migraine Headache and Objectively-assessed Sleep Among Adults with Episodic Migraine: A Prospective Cohort Study

Vgontzas, Angeliki

- P168** Does Treatment of Cervical Dystonia Reduce Migraine Frequency?
Bobker, Sarah
- P169** Thoracic CSF Venous Fistula Presenting as Spontaneous Intracranial Hypotension
Duvall, Jaclyn
- P170** Migraine History and Effectiveness of Caffeine Use in Hypnic Headache Patients
Preston, Juliette
- P171** Non-Invasive Vagus Nerve Stimulation as a Rescue Treatment for Vestibular Migraine
Beh, Shin
- P172** Observations from a Collaborative Care Headache and Hormone Clinic Model
Grosberg, Brian
- P173** A Novel Perivascular Approach to the Ultrasound-guided Glossopharyngeal Nerve Block
Anugerah, Ariana
- P174** Persistent Neurological Deficits in a Patient with CACANA1A Gene Revealing Diffuse Astrocytoma
Suneja, Aarushi
- P175** One and Done: A Case Series of Large Volume Occipital Nerve Blocks for the Treatment of Occipital Neuralgia
Mathew, Paul
- P176** Neuropathic Otagia: Rare and Treatable Ear Pains
Suneja, Aarushi
- P177** Red Ear Syndrome Case Report: A Rational Use of Erenumab
Robblee, Jennifer
- P178** Diffuse Vasogenic Leakage of Gadolinium Contrast in Patients with Syndrome of Headache and Neurological Deficits with CSF Lymphocytosis (HANDL)
Vilanilam, George
- P179** Novel Receptor Activity Mapping of Methysergide and Its Metabolite, Methylergometrine, Provides a Mechanistic Rationale for Both the Clinically Observed Efficacy and Risk of Fibrosis in Patients with Migraine
Guzman, Miguel
- P180** Serotonin Receptor Activity Profiles (5-HT_{2B} and 5-HT_{2A}) for Nine Commercialized Ergot Alkaloids Correspond to Known Risks of Fibrosis and Hallucinations
Alam, Aftab
- P181** Calcitonin Gene-related Peptide Inhibitor; Role in Treatment of Hemicrania Continua, with Potential Benefit in Controlling Diarrhea
Hussaini, Sharmeen
- P182** Development of a Novel, Clinical-stage Drug for the Prevention of Migraine Based on Receptor Activity Mapping and Achievement of a Target Receptor Profile
Armer, Thomas

- P183** Post-Traumatic Headache Is Highly Persistent over Time After TBI in Veterans
Couch, James
- P184** Sports-related Concussion in High School Wrestlers: Survey of Wrestlers and Their Parents
Goldberg, Marco
- P185** Understanding the Prevalence and Geographic Distribution of Headache Disorders Within the Veterans Health Administration
Grinberg, Amy
- P186** New Persistent Post-Concussion Headache in Children and Adolescents
Barissi, Marcus
- P187** Introducing a Nationwide Program to Improve the Care of Veterans with Headache – the Veterans Health Administration Headache Center of Excellence (HCoE) Program
Sico, Jason
- P188** Results of a Gap Analysis of Headache in Veterans and Service Members
Lindsey, Hayley
- P189** Dextromethorphan/Quinidine for Post Traumatic Migraine in Patients with Pseudobulbar Affect
Kozminski, Matthew
- P190** Rationale and Design for a Randomized, Single-Center, Double-blind, Sham-Controlled Study of Non-invasive Vagus Nerve Stimulation for the Acute and Preventive Treatment of Post-traumatic Headache
Vargas, Bert
- P191** Objectively Measured Physical Activity Among Migraineurs as a Function of Headache Activity
Rogers, Daniel
- P192** Feasibility and Acceptability of Smartphone Based Migraine Behavioral Therapy in The Neurology Outpatient Setting: A Single Arm Study
Minen, Mia
- P193** The Use of Mindfulness-Based Cognitive Therapy (MBCT) for Migraine for the Treatment of Depressive Symptoms in People with Migraine: Secondary Analysis Results from a Phase 2b Pilot Randomized Clinical Trial
Rosenberg, Lauren
- P194** Does Message Framing Help with Willingness to Pursue Behavioral Therapy: A Study in People with Migraine
Jalloh, Adama
- P195** Does Motivational Interviewing Improve Patients' Participation in Migraine Behavioral Therapy: A Pilot Single-Blinded Randomized Controlled Trial
Minen, Mia
- P196** Relationship Between Age of Onset and Psychological Factors in Migraine Patients
Sutton, Leah
- P197** Development and Implementation of "The Migraine Toolbox"
bernstein, carolyn

- P198** Integrating Physical and Mental Health in Patients with Headache: Bridging the Gap via a Transdisciplinary and Interprofessional Approach
Amorello, Brian
- P199** Assessing Diagnostic Error in Cerebral Vein Thrombosis via Detailed Chart Review
Lieberman, Ava
- P200** A Rare Case of Bilateral Internal Carotid Artery Aneurysms Presenting as Trigeminal Neuralgia
Muzammil, Syeda maria
- P201** The Presence of Headache Attributed to TMD Is Associated with Greater Psychiatric Comorbidity in Patients with Chronic TMD
Vivaldi, Daniela
- P202** Migraine Treatments Utilized by Postural Orthostatic Tachycardia Syndrome Patients
Fayyaz, Tabbassum
- P203** Squamous Cell Carcinoma as a Delayed Presentation of Supraorbital Neuralgia and Multiple Cranial Neuropathies: A Case Report
Robblee, Jennifer
- P204** "Ear Burn" as a Positional Manifestation of Gastroesophageal Reflux Disease
Arca, Karissa
- P205** Recurrent Thunderclap Headache from a Sexual Performance Enhancing Agent Marketed as All-natural
Sallowm, Yamin
- P206** Lumbar CSF Pressure vs Volume Studies May Provide Clues to Occult Underlying Pathology Associated with Headache
Lucchese, Scott
- P207** Headaches in a HIV Patient
Varma-Doyle, Aditi
- P208LB** The function of the brain that turn dysfunctional in migraine and related functional disorders
Hougaard, Kjeld
- P209LB** Analgesic effect of intranasal oxytocin in a rat model of trigeminal neuralgia
Yeomans, David
- P210LB** The Aimovig "Wear-Off": A Retrospective Case Series of Response to 14 day Dosing
George, Naveen
- P211LB** IV Valproate Sodium as a Preventive Treatment for Chronic Migraine
Riggins, Nina
- P212LB** Prognosis following discontinuation of onabotulinumtoxinA therapy in "super-responding" chronic migraine patients
Rothrock, John
- P213LB** Content validity of the HIT-6 in migraine patients: results of a systematic literature review
Houts, Carrie

- P214LB** Chronic migraine: Establishing a responder definition for the HIT-6 total score
Cady, Roger
- P215LB** Eptinezumab Demonstrated Early and Sustained Reductions in HIT-6 Total Score Over Time in Patients with Chronic Migraine in the PROMISE-2 Trial
Lipton, Richard
- P216LB** Early and Sustained Reduction in Headache Impact in People with CM After Eptinezumab Treatment: HIT-6 Item Analysis in the Phase 3 PROMISE-2 Trial
Buse, Dawn
- P217LB** Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
Winner, Paul
- P218LB** Eptinezumab Reduces the Frequency of Acute Medication Usage in Patients with Episodic or Chronic Migraine
Tepper, Stewart
- P219LB** Treatment with Eptinezumab Demonstrated Meaningful Improvements in Patients with Chronic Migraine Experiencing a High Frequency of Severe Migraines
Nagy, Abraham
- P220LB** The Eptinezumab:CGRP Complex Structure and Characterization of the Ligand Binding Interface
Misura, Kira
- P221LB** Development of nasal insulin-like growth factor-1 as a novel treatment for migraine
Kraig, Richard
- P222LB** Use of Single Pulse Transcranial Magnetic Stimulation (sTMS) to treat migraine with medication overuse: response over time
DiGuilio, Susan
- P223LB** Chronic Migraine is Highly Prevalent in General Otolaryngology; A CHEER Network Study
Teixido, Michael
- P224LB** Is stress associated with pain severity in chronic migraine?
Donoghue, Stephen
- P225LB** A Patient perspective of Complementary and Integrative Medicine (CIM) for Migraine Treatment: A social media survey
Kuruvilla, Deena
- P226LB** A retrospective analysis to evaluate the response of the addition of erenumab to onabotulinumtoxinA for the prevention of intractable chronic migraine without aura
Armanious, Mark
- P227LB** Facial temperature change after Sphenopalatine ganglion block in Primary Headache Disorders
Mathew, Shema
- P228LB** Migraine Modifies Propranolol Efficacy for Treatment of TMD Pain: SOPPRANO Randomized Controlled Trial

Tchivileva, Inna

- P229LB** Limited antinociceptive effects of delta-9-tetrahydrocannabinol in experimental models of capsaicin-induced hyperalgesia and acute pain in healthy human volunteers
Schindler, Emmanuelle
- P230LB** Assessing the Long-Term Effectiveness of Qtrypta using the Migraine-ACT: Correlation with Electronic Diary Scores
Tepper, Stewart
- P231LB** Individual-level patterns of perceived stress throughout the migraine cycle: A longitudinal cohort study using daily prospective data
Shulman, Kenneth
- P232LB** A pilot randomized controlled trial of a community-based mindfulness-based stress reduction intervention versus usual care for moderate-to-severe migraine headache
Pressman, Alice
- P233LB** Occipital neuralgia: clinical profile and sleep quality of 55 Mexican patients. Results from PREMECEF.
Marfil, Alejandro
- P234LB** Effectiveness of a Novel algorithm in the treatment of chronic migraine by reduction of work hour loss due absenteeism and presentism.
OWIESY, FARO
- P235LB** Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy
Lipton, Richard
- P236LB** Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials
Buse, Dawn
- P237LB** Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays
Conway, Charles
- P238LB** Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab
Mullin, Kathleen
- P239LB** Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials
Dodick, David
- P240LB** The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Croop, Robert
- P241LB** Rimegepant 75 mg in Subjects with Hepatic Impairment: Results of a Phase 1, Open-label, Single-dose, Parallel-group Study
Croop, Robert

- P242LB** A Single Dose of Rimegepant 75 mg Provides Pain Relief and Return to Normal Function: Results from 3 Phase 3 Trials in Adults With Migraine
Lipton, Richard
- P243LB** The Safety and Tolerability of Rimegepant 75 mg Are Similar to Placebo: Results from 3 Phase 3 Trials in Adults With Migraine
Hutchinson, Susan
- P244LB** A Single Dose of Rimegepant Demonstrates Sustained Efficacy and Low Rescue Medication Use in the Acute Treatment of Migraine: Results From 3 Phase 3 Trials
Pavlovic, Jelena
- P245LB** Rimegepant Has No Clinically Relevant Effects on ECG parameters: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects
Hanna, Michael
- P246LB** Rimegepant 75 mg Is More Effective Than Nonsteroidal Anti-inflammatory Drugs for the Acute Treatment of Migraine: Post Hoc Analysis of Data From 2 Phase 3 Trials
Blumenfeld, Andrew
- P247LB** Safety of Rimegepant 75 mg in Adults With Migraine: No Effects of Age, Sex, or Race in 3 Phase 3 Trials
Hutchinson, Susan
- P248LB** Impact of galcanezumab on total pain burden: findings from a Phase 3 randomized, double-blind, placebo-controlled study in patients with episodic cluster headache
Kuruppu, Dulanji
- P249LB** Galcanezumab treatment patterns in episodic cluster headache: findings from a Phase 3b multicenter, single-arm, open-label safety study of galcanezumab
Oakes, Tina
- P250LB** Is there an epidemic of chronic tension type headache in Washington, DC?
Rothrock, John
- P251LB** Association and Impact of Monthly Migraine Headache Frequency and Pain Intensity on Comorbidities and Concomitant Health Conditions: Results from the Migraine in America Symptoms and Treatment (MAST) Study
Munjal, Sagar
- P252LB** Headache Frequency, Disability, Treatment Optimization and Medication Use Patterns in Persons with Migraine and Co-morbid Gastric Ulcer Disease (UD): Results from Migraine in America Symptoms and Treatment (MAST) Study
Singh, Preeti
- P253LB** The Migraine Patient Journey: Diagnosis and Treatment Patterns in a Large Healthcare System, Results of the Migraine Signature Study (MSS)
Pressman, Alice
- P254LB** Direct Headache Care: Patient Outcomes Using A Membership Based, Integrative Model
Wohlgelegen, Cristina

- P255LB** Impact of Monthly Headache Day Frequency on Work Productivity and Impairment in Non-Work Activities among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment Study
Munjal, Sagar
- P256LB** New Daily Persistent Headaches in a Pediatric Population
DiSabella, Marc
- P257LB** An app to help children describe their headache. Results of the first clinical trial.
Nava, Nelly
- P258LB** Trajectory of Pediatric Migraine Preventive Medication Treatment Response: An Ancillary Study of the CHAMP Trial
Reidy, Brooke
- P259LB** Post-hoc outcomes from a Phase 3 randomized, double-blind, placebo-controlled study of galcanezumab in patients with episodic cluster headache
Martinez, James
- P260LB** Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study
Reuter, Uwe
- P261LB** A Real Headache, Professional Subjects in Migraine Trials
Shiovitz, Thomas
- P262LB** Dysgeusia rates in a multicenter, open-label, long-term, safety study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for acute treatment of migraine
Munjal, Sagar
- P263LB** Triptan-related adverse events in a multicenter, open-label, long-term, safety study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of migraine
Brand-Schieber, Elimor
- P264LB** Evaluation of the Number of Migraine Headache Days and Hours in Subjects Using DFN-02 for Acute Treatment in a Long Term Open-label safety study
Munjal, Sagar
- P265LB** Daily and Economic Burden of Living with Migraine: United States Results from the “My Migraine Voice” Survey
Shah, Shweta
- P266LB** User Acceptance of a Prefilled Auto-injector Device for Erenumab in Patients with Migraine
Mead, Jennifer
- P267LB** Is chocolate associated with more severe days in chronic migraine?
Shulman, Kenneth
- P268LB** Early Use of Erenumab in US Real World Practice
Chia, Victoria
- P269LB** Erenumab Early View: Patient Access in the United States.

Shah, Shweta

- P270LB** Erenumab prescription early view: Patient characteristics, treatment patterns and medication adherence in the United States
Shah, Shweta
- P271LB** Treatment patterns, healthcare resource use, and outcomes of patients with chronic and episodic migraines treated with erenumab: a multicenter chart-review study
Chandler, David
- P272LB** Patient satisfaction with fremanezumab treatment for chronic or episodic migraine: results from a web-based, patient survey following completion of a 1-year extension study
Lipton, Richard
- P273LB** Simulated Use of a Fremanezumab Autoinjector: Use as Intended, Ease of Use, and Comfort with Using the Autoinjector
Cowan, Robert
- P274LB** Patient preference for dosing regimen and perception of dosing flexibility with fremanezumab for chronic or episodic migraine: results from a web-based, patient survey following completion of a 1-year extension study
Cowan, Robert
- P275LB** A rare case of nervus intermedius neuralgia responsive to sphenopalatine ganglion blocks
Joseph, Rosamma
- P276LB** Rare Cause of Worsening Migraine with Aura: Iatrogenic Atrial Septal Defect Following Cardiac Ablation
Thaler, Alison
- P277LB** The Effect of Aimovig on Trigeminal Neuralgia: A Retrospective Case Series
George, Naveen
- P278LB** Migraine Features Associated with Postural Orthostatic Tachycardia Syndrome (POTS)
Mueller, Bridget
- P279LB** The degree of discomfort provoked by flickering light is strongly related to visual cortex response
Patterson Gentile, Carlyn
- P280LB** Phase 1 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range
Conway, Charles
- P281LB** Response to Mindfulness-Based Cognitive Therapy for Migraine in Chronic and Episodic Migraine: Planned Secondary Analyses of a Randomized Clinical Trial
Seng, PhD, Elizabeth
- P282LB** Spontaneous Intracranial Hypotension (SIH) Secondary to CSF Venous Fistula: Case Series
Duvall, Jaclyn
- P283LB** Risk Factors for Secondary Headache in Children and Adolescents: A Systematic Review
Velasquez, Gerardo